Breaking

Gilead says late-stage remdesivir trial shows improvement in some coronavirus patients - CNBC
Jun 01, 2020 50 secs
Patients on a five-day course were 65% more likely to have clinical improvement at day 11 versus standard of care, according to Gilead.

The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, but not statistically significant, the company said.

"Today's results showed that when treating moderate disease, a 5-day course of remdesivir led to greater clinical improvement than standard of care, adding further evidence of remdesivir's benefit to previously released study results.".

In late April, the National Institute of Allergy and Infectious Diseases released preliminary results from its own study showing Covid-19 patients who took remdesivir usually recovered after 11 days, four days faster than those who didn't take the drug.

Some health authorities in the U.S., China and other parts of the world have been using remdesivir, which was tested as a possible treatment for the Ebola outbreak, in hopes that the drug can improve the outcomes for Covid-19 patients.

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED